Trial
NCT03122106
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
National Cancer Institute (NCI)
Condition
Pancreatic Cancer
Intervention
Personalized neoantigen DNA vaccine
Why stopped
Loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-10